Transcriptomic changes induced by a new Src Family Kinase Inhibitor and proton radiation in glioblastoma cells

Glioblastoma multiforme (GBM) is a central nervous system tumour. The current standard care for GMB is surgical resection, followed by conventional radiotherapy (RT) often combined with daily drug (temozolomide) administration. However, these treatment modalities are not currently curative and the resistance to both chemotherapy and RT plans is the main cause of GBM care failures. In this scenario, proton therapy (PT) could be used as a successful strategy for GBM treatment, being able to regulate the balance between tumour control and the normal tissue tolerance. In addition, new drugs could be used as radiosensitizing agents combined with PT in order to optimize GBM care. In this work we analyzed the GEP of the U87 MG human glioblastoma cell line, after treatment with PT alone or in combination with a new targeted compound, named Si306 (property of Lead Discovery Siena, Siena, Italy). We described GEP induced by both treatments, highlighting for the first time, the cell pathways induced by Si306. Summarizing, our results suggesting this compound as a novel possible candidate to treat GBM in combination with PT. We performed two-color hybridization experiments using Agilent Technologies whole human genome 4x44K microarrays after i) proton treatment and ii)new farmacological coumpound named Si306 and radiation (protons) combined treatments; in U87 MG human glioblastoma cell line. Samples were named as follow: U87_2Gy; U87_10Gy; U87 2Gy + 10µM Si306; U87 10Gy + 10µM Si306.